SCHEMBL7068397

SCHEMBL7068397

NCc1ccc2[nH]c(Cc3nc4cc(C(=O)NCC=Cc5ccccc5)ccc4[nH]3)nc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 6/20 0.42
HDAC1 Q13547 4/20 0.42
HDAC3 O15379 3/20 0.42
HDAC4 P56524 3/20 0.42
HDAC7 Q8WUI4 3/20 0.42
HDAC2 Q92769 3/20 0.42
HDAC10 Q969S8 3/20 0.42
HDAC11 Q96DB2 3/20 0.42
HDAC8 Q9BY41 3/20 0.42
HDAC9 Q9UKV0 3/20 0.42
HDAC5 Q9UQL6 3/20 0.42
ALDH1A1 P00352 3/20 0.40
PRSS1 P07477 1/20 0.40
PRSS2 P07478 1/20 0.40
PRSS3 P35030 1/20 0.40
TPSAB1 Q15661 1/20 0.40
CACNA1B Q00975 1/20 0.40
TSHR P16473 1/20 0.39
MAPK10 P53779 1/20 0.39
PIN1 Q13526 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7068388 1.00 HDAC6 (0.42) HDAC6HDAC1HDAC3HDAC4HDAC7
SCHEMBL7070258 0.84 PLAU (0.53) HDAC6ALDH1A1TSHRMAPK10SMN1; SMN2
SCHEMBL7068309 0.82 NAMPT (0.50) HDAC6ALDH1A1TSHRPKMKDM4E
SCHEMBL7069769 0.81 POLB (0.50) HDAC6ALDH1A1SMN1; SMN2KDM4E
SCHEMBL7074425 0.81 ALDH1A1 (0.46) ALDH1A1PRSS1PRSS2PRSS3TPSAB1
SCHEMBL7073473 0.80 HTR2C (0.47) ALDH1A1TSHRMAPK10GAACYP2C9
SCHEMBL7071815 0.80 ALDH1A1 (0.44) HDAC6ALDH1A1PKM
SCHEMBL7400914 0.80 HDAC6 (0.49) HDAC6ALDH1A1SMN1; SMN2KDM4ECYP1A2
SCHEMBL7069837 0.80 ALDH1A1 (0.47) ALDH1A1TPSAB1PKMCYP2C9HPGD
SCHEMBL7075818 0.79 NPC1 (0.55) ALDH1A1TSHRSMN1; SMN2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212120-A1 Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders AXYS PHARMACEUTICALS, INC. (US) 2003-11-13 US disclosed
US-6562854-B2 Antiinflammatory agents; respiratory system disorders AXYS PHARMACEUTICALS, INC. 2003-05-13 US disclosed
US-20010053779-A1 Novel compounds and compositions for treating diseases asociated with protease activity Celera Corporation 2001-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053779-A1 Novel compounds and compositions for treating diseases asociated with protease activity CMA1, CPA3, TPSG1 HDAC6 379/4885HDAC1 659/4885HDAC3 1325/4885
US-20030212120-A1 Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders CMA1, TPSG1, TPSD1 HDAC6 709/4885HDAC1 960/4885HDAC3 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.